The guidance raise and strong beat confirm improving operational momentum and balance sheet deleveraging. However, the Nashik supply disruption creates H2 uncertainty, monitor management's remediation progress and any further guidance revisions. The Gwyn Lo launch and Tyrvaya monetization add pipeline value but are not near-term revenue drivers. The stock may re-rate on the combination of earnings growth and debt reduction, but the $100-150M revenue headwind from Nashik limits upside until resolved.
Drug in focus
VTRS drug pipeline →Tyrvaya
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized since October 2021.
- Next catalyst
- None dated
What to watchTyrvaya is now owned by Harrow (HROW), not Viatris (VTRS). The next catalyst is Harrow's commercial execution: Tyrvaya closed on October 5, 2026, so its contribution to Harrow's Q4 2026 and full-year 2027 results will be the key metric to watch. Harrow expects Tyrvaya to add more than $30M in 2027 revenue. For Viatris, Tyrvaya is a divested non-core asset with no further impact.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $16.29entry
- T+1 · 3mo ago +0.86%α +0.25% · $16.43
- T+5 · 3mo ago −1.53%α −2.75% · $16.04
- T+20 · 3mo ago +3.99%α +3.39% · $16.94
- T+60 · 18d ago +16.85%α +18.52% · $19.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (15% above $0.60 est) and total revenue of $3.76B (+5% YoY, 2.4% above consensus). The company raised midpoints of all 2026 guidance metrics, revenue to $14.75B, adjusted EBITDA to $4.4B, adjusted EPS to $2.52, and free cash flow to $2.2B, while reducing gross leverage to 2.9x and returning $550M to shareholders. Material headwinds from the Nashik facility disruption ($100-150M H2 revenue impact) are partially offset by FDA approval of Gwyn Lo and the Tyrvaya sale.
Key Financial Metrics
Key Facts
- Q2 adjusted EPS $0.69 vs consensus $0.60 (+15% beat)
- Total revenue $3.76B vs consensus $3.67B (+2.4% beat); reported growth +5%, operational +4%
- Raised 2026 guidance midpoints: revenue $14.75B (from $14.70B), adj. EBITDA $4.40B (from $4.30B), adj. EPS $2.52 (from $2.40), FCF $2.20B (from $2.15B)
- Gross leverage ratio reduced to 2.9x; $900M debt repaid, refinanced with €650M notes
- Returned ~$550M to shareholders YTD including $270M in share repurchases at $16.42 avg
- FDA approved Gwyn Lo contraceptive patch; signed Tyrvaya sale for $30M upfront + $70M milestones
- Nashik facility disruption expected to impact $100-150M of H2 2026 total revenue
- Adjusted EBITDA $1.19B (+10% reported, +8% operational); free cash flow ex-items $449M in Q2
Financial Impact
Guidance midpoint raise of $0.12 on adjusted EPS (+5%) and $100M on EBITDA (+2.3%) vs. prior guidance, partially offset by $100-150M Nashik revenue headwind
Risk Factors
- Nashik facility disruption could be worse than guided $100-150M hit to H2 revenue
- Generics pricing pressure and competition on key brands (EpiPen, Lyrica, Viagra)
- Currency headwinds from strong USD (operational growth 3.5% vs reported 5%)
- Execution risk on new product launches (Gwyn Lo, MR-107A-02) and pipeline milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001792044-26-000037 |
| Document: vtrs-20260806.htm | 0001792044-26-000037 |
| Document: 0001792044-26-000037-index-headers.html | 0001792044-26-000037 |
| Document: 0001792044-26-000037-index.html | 0001792044-26-000037 |
| Document: 0001792044-26-000037.txt | 0001792044-26-000037 |
| 8-K Data (Synthetic) | 0001792044-26-000037 |
Track record
22 reports on VTRS
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +13.58% at T+20 after the Oct 16, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 4/10 Entry $20.51 Now $20.49 −0.10% settles Feb 16
- Nov 17, 2026today Press Release Neutral 4/10 Entry $20.89 Now $20.49 −1.91% settles Feb 16
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $20.84 Now $20.49 −1.68% settles Feb 12
- Nov 6, 202611d ago SC 13G/A Neutral 2/10 Entry $19.91 Now $20.49 +2.91% settles Feb 4
- Nov 5, 202612d ago 8-K Mixed 6/10 Entry $18.97 Now $20.49 +8.01% settles Feb 3
- Nov 4, 202613d ago Press Release Neutral 2/10 Entry $19.22 Now $20.49 +6.61% settles Feb 2
- Oct 30, 202618d ago Press Release Bullish 6/10 Entry $19.04 Now $20.49 +7.64% settles Jan 28
- Oct 29, 202619d ago Institutional Cluster Bullish 4/10 Entry $19.20 Now $20.49 +6.72% settles Jan 27
- Oct 16, 20264w ago Press Release Bullish 6/10 Entry $18.26 Now $20.49 +12.21% settles Jan 14
- Oct 8, 20265w ago 8-K Bullish 7/10 Entry $17.44 Now $20.49 +17.49% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers